According to a recent study, Taiwanese researchers found that DUSP2 gene deficiency aids cancer cell growth, especially in ...

In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H 2025Continued solid ...

Oncotelic Therapeutics, a leader in RNA-based therapeutics, is pleased to announce that Vuong Trieu, Ph.D., Chairman & CEO, will be delivering a featured presentation at the SWCR 2025 Conference on ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

RenovoRx, Inc. ("RenovoRx" or the "Company") , a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its ...

According to recent lawsuits, Delaware’s waterways have fallen victim to contamination by “forever chemicals,” or chemicals that remain in the environment for up to thousands of years after exposure.

Piper Sandler initiated coverage on Merus N.V. (NASDAQ:MRUS), a $2.8 billion market cap biotech company, with an Overweight rating and a price target of $84.00. According to InvestingPro data, the ...

The National Medical Commission (NMC) has issued Guidelines for the competency-based postgraduate training programme for MCh ...